Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07614022 | A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL) | PHASE1 | NOT YET_RECRUITING | 26 | — | — | Oct 1, 2026 | Mar 1, 2030 | Jun 5, 2026 | 2 | United States |
Binary variable indicating if a Dose Limiting Toxicity (DLT) occurred.
Binary variable indicating if a Dose Limiting Toxicity (DLT) occurred.
| Arm | Type | Description |
|---|---|---|
| Combination of LP-118, ponatinib, dexamethasone, blinatumomab and methotrexate | EXPERIMENTAL | LP-118 will be given as tablets of 10mg or 100mg during the induction II course only in combination with ponatinib, dexamethasone, methotrexate and blinatumomab. . Ponatinib, dexamethasone and methotrexate dosing will remain fixed, whereas LP-118 dosing will be dependent on the dose level to which a participant is assigned. |
| Name | Type | Description |
|---|---|---|
| LP-118 | DRUG | s LP-118 dosing will be dependent on the dose level to which a participant is assigned: * 50mg PO * 100mg PO * 200mg PO * 300mg PO |
Inclusion Criteria: * Ability to understand and willingness to sign an IRB-approved informed consent. * Age ≥ 18 years at the time of consent. * ECOG Performance Status (PS) ≤ 2. * Histological or cytological confirmation of newly diagnosed CD19-positive Philadelphia-chromosome/BCR::ABL1-positive A...